Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK

BACKGROUND: Interleukin-17A (IL-17A) antagonists are a recent innovation for treating psoriatic arthritis (PsA). There are currently no cost-effectiveness analyses (CEAs) comparing the IL-17A antagonists ixekizumab and secukinumab in PsA from a UK perspective. OBJECTIVE: We conducted a CEA from the...

Descripción completa

Detalles Bibliográficos
Autores principales: Schweikert, Bernd, Malmberg, Chiara, Åkerborg, Örjan, Kumar, Gayathri, Nott, Debby, Kiri, Sandeep, Sapin, Christophe, Hartz, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688884/
https://www.ncbi.nlm.nih.gov/pubmed/32166657
http://dx.doi.org/10.1007/s41669-020-00202-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688884/
https://www.ncbi.nlm.nih.gov/pubmed/32166657
http://dx.doi.org/10.1007/s41669-020-00202-1

Ejemplares similares